Molecular regulation of polycystic ovary syndrome: altered gene expression levels in mouse models pretreatment and post-treatment.


Journal

Zygote (Cambridge, England)
ISSN: 1469-8730
Titre abrégé: Zygote
Pays: England
ID NLM: 9309124

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 4 11 2021
medline: 3 6 2022
entrez: 3 11 2021
Statut: ppublish

Résumé

Polycystic ovary syndrome (PCOS) is a complex disorder and genetic factors are believed to play a role. The main aim was to investigate expression levels of genes involved in PI3K/AKT signalling pathway pretreatment and post-treatment. Mouse models of PCOS were generated. Group one included control mice with no polycystic ovaries (n = 4), Group 2 included a PCOS mouse model (n = 8), Group 3 included PCOS mice treated with clomiphene citrate (n = 7) and Group 4 included PCOS mice treated with clomiphene citrate, metformin and pioglitazone (n = 8). Histochemical analyses were performed. Total RNA was extracted and cDNA was synthesized. Irs, Akt1 and Akt2, mTor and Pdpk1 gene expression levels were evaluated by RT-PCR amplification. In Group 1, cortex and medulla were evaluated as normal; in Group 2, ovarian cortex was composed of immature oocytes and cystic follicles with atretic follicles. In Groups 3 and 4, follicles were in the process of normal follicle differentiation. The expression levels of Akt1 and Pi3k were significantly different (P < 0.0001) between Groups 1 and 2. The significant differences in expression levels of Pi3k and Akt1 were also observed between the Group 1 and both Groups 3 and 4 (P < 0.0001). Furthermore, significant variations of the expression levels of mTor between Groups 1 and 4 were observed. The extrapolation of results of this study may imply that follicular development may be regulated by molecular pathways involving Pi3k, Akt1 and mTor expression. Therefore, genes in the PI3K/AKT pathway may have a direct regulatory role in the development of PCOS.

Identifiants

pubmed: 34727997
pii: S0967199421000769
doi: 10.1017/S0967199421000769
doi:

Substances chimiques

Clomiphene 1HRS458QU2
3-Phosphoinositide-Dependent Protein Kinases EC 2.7.11.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-357

Auteurs

P Tulay (P)

Near East University, Faculty of Medicine, Department of Medical Genetics, Nicosia, Cyprus.
Near East University, DESAM Research Institute, Nicosia, Cyprus.

T Onal (T)

Manisa Celal Bayar University, Faculty Medicine, Department of Histology and Embryology, Manisa, Turkey.

S Vatansever (S)

Near East University, DESAM Research Institute, Nicosia, Cyprus.
Manisa Celal Bayar University, Faculty Medicine, Department of Histology and Embryology, Manisa, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH